Premium
Progeria: How much information do we know?
Author(s) -
Glymph Kelly,
Agazuma Keshia,
Raynes Edilberto,
Waller Lauren,
Coker Karen,
Michaels Natalie,
Banting Imelda
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.1058.3
Subject(s) - progeria , lmna , life expectancy , gerontology , medicine , premature aging , quality of life (healthcare) , pediatrics , family medicine , psychiatry , genetics , biology , environmental health , population , physiology , lamin , nursing , nucleus , gene
Hutchinson‐Gilford Progeria syndrome, also known as Progeria, is a rare genetic disorder, caused by LMNA gene mutation resulting in segmental aging syndrome. It affects one in 20 million people worldwide and has an estimated prevalence of one in four million. It has no sex predilection and affects all races. The syndrome does not manifest signs and symptoms until 9 to 12 months of life and the life expectancy is often only until age 12 to 16 years old (Mayo Clinic, 2016). The purpose of the study was to peruse the available research and to disseminate information to the public in order to increase awareness of the syndrome, and to rectify any misconceptions about the disorder. Using a systematic review of literature, the findings suggested that a multi‐disciplinary approach is needed to help the affected children increase their quality of life. Edilberto A. Raynes, MD, PhD; Kelly Glymph, SPT; Keshia Agazuma, SPT; Lauren Waller, SPT; Karen Coker, PT, DPT, CWS, C/NDT, FACCWS; Natalie Michaels, PT, EdD, GCS Emeritus, and Imelda Banting, PT, MD